{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:38:02Z","timestamp":1783953482109,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The intricate interplay between immune and stromal cells within the tumour microenvironment (TME) significantly influences tumour progression. Myeloid cells, including tumour-associated macrophages (TAMs), neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs), contribute to immune suppression in the TME (Nakamura and Smyth in Cell Mol Immunol 17(1):1\u201312 (2020).\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/s41423-019-0306-1\">https:\/\/doi.org\/10.1038\/s41423-019-0306-1<\/jats:ext-link>\n                    ; DeNardo and Ruffell in Nat Rev Immunol 19(6):369\u2013382 (2019).\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/s41577-019-0127-6\">https:\/\/doi.org\/10.1038\/s41577-019-0127-6<\/jats:ext-link>\n                    ). This poses a significant challenge for novel immunotherapeutics that rely on host immunity to exert their effect. This systematic review explores the preclinical evidence surrounding the inhibition of phosphoinositide 3-kinase gamma (PI3K\u03b3) as a strategy to reverse myeloid-driven immune suppression in solid tumours. EMBASE, MEDLINE, and PubMed databases were searched on 6 October 2022 using keyword and subject heading terms to capture relevant studies. The studies, focusing on PI3K\u03b3 inhibition in animal models, were subjected to predefined inclusion and exclusion criteria. Extracted data included tumour growth kinetics, survival endpoints, and immunological responses which were meta-analysed. PRISMA and MOOSE guidelines were followed. A total of 36 studies covering 73 animal models were included in the review and meta-analysis. Tumour models covered breast, colorectal, lung, skin, pancreas, brain, liver, prostate, head and neck, soft tissue, gastric, and oral cancer. The predominant PI3K\u03b3 inhibitors were IPI-549 and TG100-115, demonstrating favourable specificity for the gamma isoform. Combination therapies, often involving chemotherapy, radiotherapy, immune checkpoint inhibitors, biological agents, or vaccines, were explored in 81% of studies. Analysis of tumour growth kinetics revealed a statistically significant though heterogeneous response to PI3K\u03b3 monotherapy, whereas the tumour growth in combination treated groups were more consistently reduced. Survival analysis showed a pronounced increase in median overall survival with combination therapy. This systematic review provides a comprehensive analysis of preclinical studies investigating PI3K\u03b3 inhibition in myeloid-driven tumour immune suppression. The identified studies underscore the potential of PI3K\u03b3 inhibition in reshaping the TME by modulating myeloid cell functions. The combination of PI3K\u03b3 inhibition with other therapeutic modalities demonstrated enhanced antitumour effects, suggesting a synergistic approach to overcome immune suppression. These findings support the potential of PI3K\u03b3-targeted therapies, particularly in combination regimens, as a promising avenue for future clinical exploration in diverse solid tumour types.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s00262-024-03779-2","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T09:08:23Z","timestamp":1722935303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature"],"prefix":"10.1007","volume":"73","author":[{"given":"Haonan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon Nicole","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keaton Ian","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"1","key":"3779_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ (2020) Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol 17(1):1\u201312. https:\/\/doi.org\/10.1038\/s41423-019-0306-1","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"3779_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19(6):369\u2013382. https:\/\/doi.org\/10.1038\/s41577-019-0127-6","journal-title":"Nat Rev Immunol"},{"key":"3779_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/030089161109700518","volume":"97","author":"I Caras","year":"2011","unstructured":"Caras I et al (2011) Influence of tumor cell culture supernatants on macrophage functional polarization: in vitro models of macrophage-tumor environment interaction. Tumori 97:647\u2013654","journal-title":"Tumori"},{"key":"3779_CR4","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.4049\/jimmunol.176.8.5023","volume":"176","author":"T Hagemann","year":"2006","unstructured":"Hagemann T et al (2006) Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176:5023\u20135032","journal-title":"J Immunol"},{"key":"3779_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ et al (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14\u201320","journal-title":"Immunity"},{"issue":"4","key":"3779_CR6","doi-asserted-by":"publisher","first-page":"e1118599","DOI":"10.1080\/2162402X.2015.1118599","volume":"5","author":"R Ma","year":"2016","unstructured":"Ma R et al (2016) Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression. Oncoimmunology 5(4):e1118599","journal-title":"Oncoimmunology"},{"key":"3779_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10555-011-9340-x","volume":"31","author":"P Cirri","year":"2012","unstructured":"Cirri P, Chiarugi P (2012) Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev 31:195\u2013208","journal-title":"Cancer Metastasis Rev"},{"key":"3779_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q et al (2023) Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther 8:320","journal-title":"Signal Transduct Target Ther"},{"key":"3779_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22:275\u2013281","journal-title":"Semin Cancer Biol"},{"key":"3779_CR10","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662\u20136667","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"3779_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1541-7786.MCR-13-0682","volume":"12","author":"S Joshi","year":"2014","unstructured":"Joshi S, Singh AR, Zulcic M, Durden DL (2014) A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1\u03b1 and HIF2\u03b1 stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res 12(10):1520\u20131531","journal-title":"Mol Cancer Res"},{"issue":"7","key":"3779_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1517\/14728222.2016.1139085","volume":"20","author":"S Serini","year":"2016","unstructured":"Serini S, Ottes Vasconcelos R, Fasano E, Calviello G (2016) Epigenetic regulation of gene expression and M2 macrophage polarization as new potential omega-3 polyunsaturated fatty acid targets in colon inflammation and cancer. Expert Opin Therap Targets 20(7):843\u2013858","journal-title":"Expert Opin Therap Targets"},{"key":"3779_CR13","doi-asserted-by":"publisher","first-page":"836223","DOI":"10.3389\/fimmu.2022.836223","volume":"13","author":"Y Niu","year":"2022","unstructured":"Niu Y, Chen J, Qiao Y (2022) Epigenetic modifications in tumor-associated macrophages: a new perspective for an old foe. Front Immunol 13:836223","journal-title":"Front Immunol"},{"issue":"11","key":"3779_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","volume":"22","author":"SM Lanahan","year":"2022","unstructured":"Lanahan SM, Wymann MP, Lucas CL (2022) The role of PI3K\u03b3 in the immune system: new insights and translational implications. Nat Rev Immunol 22(11):687\u2013700. https:\/\/doi.org\/10.1038\/s41577-022-00701-8","journal-title":"Nat Rev Immunol"},{"key":"3779_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM et al (2016) PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539:437\u2013442","journal-title":"Nature"},{"issue":"12","key":"3779_CR16","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS et al (2023) Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial. Clin Cancer Res 29(12):2210\u20132219. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3313","journal-title":"Clin Cancer Res"},{"key":"3779_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2018.10.020","volume":"442","author":"AA De Vera","year":"2019","unstructured":"De Vera AA et al (2019) Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: in vitro and in vivo. Cancer Lett 442:91\u2013103","journal-title":"Cancer Lett"},{"key":"3779_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/2326-6066.CIR-18-0272","volume":"7","author":"H Zha","year":"2019","unstructured":"Zha H et al (2019) Intracellular activation of complement C3 leads to PD-L1 antibody treatment resistance by modulating tumor-associated macrophages. Cancer Immunol Res 7:193\u2013207","journal-title":"Cancer Immunol Res"},{"key":"3779_CR19","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.ajpath.2020.07.013","volume":"190","author":"WC Chung","year":"2020","unstructured":"Chung WC, Zhou X, Atfi A, Xu K (2020) PIK3CG is a potential therapeutic target in androgen receptor-indifferent metastatic prostate cancer. Am J Pathol 190:2194\u20132202","journal-title":"Am J Pathol"},{"key":"3779_CR20","doi-asserted-by":"publisher","first-page":"e003762","DOI":"10.1136\/jitc-2021-003762","volume":"10","author":"YN Yoon","year":"2022","unstructured":"Yoon YN et al (2022) PI3K\u03b4\/\u03b3 inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation. J Immunother Cancer 10:e003762","journal-title":"J Immunother Cancer"},{"key":"3779_CR21","doi-asserted-by":"publisher","first-page":"1900327","DOI":"10.1002\/advs.201900327","volume":"6","author":"H Qin","year":"2019","unstructured":"Qin H et al (2019) PI3Kgamma inhibitor attenuates immunosuppressive effect of poly(l-glutamic acid)-combretastatin A4 conjugate in metastatic breast cancer. Adv Sci 6:1900327","journal-title":"Adv Sci"},{"key":"3779_CR22","doi-asserted-by":"publisher","first-page":"1900037","DOI":"10.1002\/advs.201900037","volume":"6","author":"M Yu","year":"2019","unstructured":"Yu M et al (2019) Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy. Adv Sci 6:1900037","journal-title":"Adv Sci"},{"key":"3779_CR23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/2326-6066.CIR-17-0143","volume":"5","author":"P Foubert","year":"2017","unstructured":"Foubert P, Kaneda MM, Varner JA (2017) PI3K\u03b3 activates integrin \u03b14 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol Res 5:957\u2013968","journal-title":"Cancer Immunol Res"},{"key":"3779_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","volume":"138","author":"M Li","year":"2018","unstructured":"Li M et al (2018) Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 138:696\u2013711","journal-title":"Circulation"},{"key":"3779_CR25","doi-asserted-by":"publisher","first-page":"e2009290118","DOI":"10.1073\/pnas.2009290118","volume":"118","author":"J Li","year":"2021","unstructured":"Li J et al (2021) PI3K\u03b3 inhibition suppresses microglia\/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proc Natl Acad Sci U S A 118:e2009290118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3779_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ejca.2021.08.029","volume":"157","author":"MG Han","year":"2021","unstructured":"Han MG, Jang BS, Kang MH, Na D, Kim IA (2021) PI3K\u03b3\u03b4 inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. Eur J Cancer 157:450\u2013463","journal-title":"Eur J Cancer"},{"key":"3779_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ccr.2011.05.005","volume":"19","author":"D Martin","year":"2011","unstructured":"Martin D et al (2011) PI3K\u03b3 mediates Kaposi\u2019s sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 19:805\u2013813","journal-title":"Cancer Cell"},{"key":"3779_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-30543-w","volume":"13","author":"X Guan","year":"2022","unstructured":"Guan X et al (2022) Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis. Nat Commun 13:1\u201317","journal-title":"Nat Commun"},{"key":"3779_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ajps.2022.06.001","volume":"17","author":"S Wang","year":"2022","unstructured":"Wang S et al (2022) Non-cytotoxic nanoparticles re-educating macrophages achieving both innate and adaptive immune responses for tumor therapy-NC-ND license. Asian J Pharm Sci 17:557\u2013570","journal-title":"Asian J Pharm Sci"},{"key":"3779_CR30","doi-asserted-by":"publisher","first-page":"2100712","DOI":"10.1002\/advs.202100712","volume":"8","author":"D Ding","year":"2021","unstructured":"Ding D et al (2021) Multifunctional nanodrug mediates synergistic photodynamic therapy and MDSCs-targeting immunotherapy of colon cancer. Adv Sci 8:2100712","journal-title":"Adv Sci"},{"issue":"12","key":"3779_CR31","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1016\/j.ymthe.2022.05.008","volume":"30","author":"Y Liu","year":"2022","unstructured":"Liu Y et al (2022) Overcoming resistance to oncolytic virus M1 by targeting PI3K-\u03b3 in tumor-associated myeloid cells. Mol Ther 30(12):3677\u20133693. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.008","journal-title":"Mol Ther"},{"key":"3779_CR32","doi-asserted-by":"publisher","first-page":"e003564","DOI":"10.1136\/jitc-2021-003564","volume":"10","author":"Y Du","year":"2022","unstructured":"Du Y et al (2022) Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3K\u03b3 inhibitor can enhance immunogenicity and eradicate tumors. J Immunother Cancer 10:e003564","journal-title":"J Immunother Cancer"},{"key":"3779_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau O et al (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539:443\u2013447","journal-title":"Nature"},{"key":"3779_CR34","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S250171","author":"J Chang","year":"2020","unstructured":"Chang J et al (2020) Targeting PIK3CG in combination with paclitaxel as a potential therapeutic regimen in claudin-low breast cancer. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S250171","journal-title":"Cancer Manag Res"},{"key":"3779_CR35","doi-asserted-by":"publisher","first-page":"2102182","DOI":"10.1002\/advs.202102182","volume":"9","author":"X Liu","year":"2022","unstructured":"Liu X et al (2022) Targeting PI3K\u03b3\/AKT pathway remodels LC3-associated phagocytosis induced immunosuppression after radiofrequency ablation. Adv Sci 9:2102182","journal-title":"Adv Sci"},{"key":"3779_CR36","doi-asserted-by":"publisher","first-page":"20414","DOI":"10.1021\/acsnano.1c08826","volume":"15","author":"Y Shen","year":"2021","unstructured":"Shen Y et al (2021) Tailoring chemoimmunostimulant bioscaffolds for inhibiting tumor growth and metastasis after incomplete microwave ablation. ACS Nano 15:20414\u201320429","journal-title":"ACS Nano"},{"key":"3779_CR37","doi-asserted-by":"publisher","first-page":"119239","DOI":"10.1016\/j.ijpharm.2020.119239","volume":"581","author":"M Jiang","year":"2020","unstructured":"Jiang M et al (2020) Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. Int J Pharm 581:119239","journal-title":"Int J Pharm"},{"key":"3779_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","volume":"19","author":"MC Schmid","year":"2011","unstructured":"Schmid MC et al (2011) Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3K\u03b3, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19:715\u2013727","journal-title":"Cancer Cell"},{"key":"3779_CR39","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/10717544.2019.1642418","volume":"26","author":"G Li","year":"2019","unstructured":"Li G, Zhao L (2019) Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment. Drug Deliv 26:756\u2013764","journal-title":"Drug Deliv"},{"key":"3779_CR40","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/0008-5472.CAN-16-2534","volume":"77","author":"RJ Davis","year":"2017","unstructured":"Davis RJ et al (2017) Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kd\/g. Cancer Res 77:2607\u20132619","journal-title":"Cancer Res"},{"key":"3779_CR41","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1126\/scitranslmed.abl3649","volume":"14","author":"Y Song","year":"2022","unstructured":"Song Y et al (2022) Albumin nanoparticle containing a PI3K\u03b3 inhibitor and paclitaxel in combination with \u03b1-PD1 induces tumor remission of breast cancer in mice. Sci Transl Med 14:3649","journal-title":"Sci Transl Med"},{"key":"3779_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jconrel.2019.07.039","volume":"309","author":"X Zhang","year":"2019","unstructured":"Zhang X, Shen L, Liu Q, Hou L, Huang L (2019) Inhibiting PI3 kinase-\u03b3 in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. J Control Release 309:173\u2013180","journal-title":"J Control Release"},{"key":"3779_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10014-020-00357-z","volume":"37","author":"T Miyazaki","year":"2020","unstructured":"Miyazaki T et al (2020) Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K\u03b3 inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathol 37:41\u201349","journal-title":"Brain Tumor Pathol"},{"key":"3779_CR44","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/2159-8290.CD-15-1346","volume":"870","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM et al (2016) Macrophage PI3Kg drives pancreatic ductal adenocarcinoma progression. Cancer Discov 870:870\u2013885","journal-title":"Cancer Discov"},{"key":"3779_CR45","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1111\/cas.14616","volume":"111","author":"Q Luo","year":"2020","unstructured":"Luo Q et al (2020) Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer. Cancer Sci 111:4000\u20134011","journal-title":"Cancer Sci"},{"issue":"6","key":"3779_CR46","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/1535-7163.MCT-20-0961","volume":"20","author":"LS Carnevalli","year":"2021","unstructured":"Carnevalli LS et al (2021) Macrophage activation status rather than repolarization is associated with enhanced checkpoint activity in combination with PI3K\u03b3 Inhibition. Mol Cancer Therap 20(6):1080\u20131091. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0961","journal-title":"Mol Cancer Therap"},{"key":"3779_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-99269-x","volume":"12","author":"Y Xu","year":"2022","unstructured":"Xu Y et al (2022) The efficacy of PI3K\u03b3 and EGFR inhibitors on the suppression of the characteristics of cancer stem cells. Sci Rep 12:1\u201311","journal-title":"Sci Rep"},{"key":"3779_CR48","doi-asserted-by":"publisher","first-page":"2104619","DOI":"10.1002\/advs.202104619","volume":"9","author":"S Li","year":"2022","unstructured":"Li S et al (2022) Engineering ROS-responsive bioscaffolds for disrupting myeloid cell-driven immunosuppressive niche to enhance PD-L1 blockade-based postablative immunotherapy. Adv Sci 9:2104619","journal-title":"Adv Sci"},{"key":"3779_CR49","doi-asserted-by":"publisher","first-page":"101597","DOI":"10.1016\/j.nantod.2022.101597","volume":"46","author":"X Han","year":"2022","unstructured":"Han X et al (2022) Genetically engineered exosomes for targetedly preventing premetastatic niche formation and suppressing postoperative melanoma lung metastasis. Nano Today 46:101597","journal-title":"Nano Today"},{"key":"3779_CR50","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s12276-020-0436-7","volume":"52","author":"YS Lee","year":"2020","unstructured":"Lee YS et al (2020) The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3K\u03b3. Exp Mol Med 52:815\u2013831","journal-title":"Exp Mol Med"},{"key":"3779_CR51","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1541-7786.MCR-13-0682","volume":"12","author":"S Joshi","year":"2014","unstructured":"Joshi S, Singh AR, Zulcic M, Durden DL (2014) A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1alpha and HIF2alpha stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res 12:1520\u20131531","journal-title":"Mol Cancer Res"},{"key":"3779_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369\u2013382","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3779_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S et al (2023) Macrophages in immunoregulation and therapeutics. Signal Transd Target Ther 8(1):207. https:\/\/doi.org\/10.1038\/s41392-023-01452-1","journal-title":"Signal Transd Target Ther"},{"key":"3779_CR54","doi-asserted-by":"publisher","first-page":"e9342","DOI":"10.15252\/emmm.201809342","volume":"10","author":"KI Jones","year":"2018","unstructured":"Jones KI et al (2018) Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol Med 10:e9342","journal-title":"EMBO Mol Med"},{"key":"3779_CR55","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1053\/j.gastro.2016.02.070","volume":"150","author":"L Seifert","year":"2016","unstructured":"Seifert L et al (2016) Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice. Gastroenterology 150:1659-1672.e5","journal-title":"Gastroenterology"},{"issue":"9","key":"3779_CR56","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1021\/acsmedchemlett.6b00238","volume":"7","author":"CA Evans","year":"2016","unstructured":"Evans CA et al (2016) Discovery of a selective phosphoinositide-3-kinase (PI3K)-\u03b3 inhibitor (IPI-549) as an immuno-oncology clinical candidate. ACS Med Chem Lett 7(9):862\u2013867. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00238","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"3779_CR57","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1042\/BST0350204","volume":"35","author":"J Doukas","year":"2007","unstructured":"Doukas J et al (2007) Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans 35(2):204\u2013206","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"3779_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet MJ, Michielin O, Migliorini D (2022) Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol 19(6):402\u2013421. https:\/\/doi.org\/10.1038\/s41571-022-00620-6","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3779_CR59","doi-asserted-by":"publisher","first-page":"2368249","DOI":"10.1155\/2019\/2368249","volume":"2019","author":"MAF Yahaya","year":"2019","unstructured":"Yahaya MAF et al (2019) Tumour-associated macrophages (TAMs) in colon cancer and how to reeducate them. J Immunol Res 2019(1):2368249. https:\/\/doi.org\/10.1155\/2019\/2368249","journal-title":"J Immunol Res"},{"key":"3779_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4048\/jbc.2019.22.e5","volume":"22","author":"H Jeong","year":"2019","unstructured":"Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY (2019) Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer 22:38","journal-title":"J Breast Cancer"},{"key":"3779_CR61","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20221659","author":"B Yi","year":"2023","unstructured":"Yi B et al (2023) Prognostic significance of tumor-associated macrophages polarization markers in lung cancer: a pooled analysis of 5105 patients. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20221659"},{"key":"3779_CR62","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S196951","author":"M Yu","year":"2019","unstructured":"Yu M et al (2019) Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S196951","journal-title":"Cancer Manag Res"},{"key":"3779_CR63","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ebiom.2016.02.024","volume":"6","author":"RB Holmgaard","year":"2016","unstructured":"Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD (2016) Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 6:50\u201358","journal-title":"EBioMedicine"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03779-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T02:03:45Z","timestamp":1726452225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03779-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3779"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03779-2","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.12.593156","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"204"}}